Article
Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease.
PloS one - 1 Jan 2016
Hansen Henrik H, Fabricius Katrine, Barkholt Pernille, Kongsbak-Wismann Pernille, Schlumberger Chantal, Jelsing Jacob, Terwel Dick, Termont Annelies, Pyke Charles, Knudsen Lotte Bjerre, Vrang Niels
Abstract excerpt
One of the major histopathological hallmarks of Alzheimer's disease (AD) is cerebral deposits of extracellular β-amyloid peptides. Preclinical studies have pointed to glucagon-like peptide 1 (GLP-1) receptors as a potential novel target in the treatment of AD. GLP-1 receptor agonists, including exendin-4 and liraglutide, have been shown to promote plaque-lowering and mnemonic effects of in a number of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.